Q2 saw 11% TRCV and 4% revenue growth year-over-year, with strong performance in Experience and Governance segments. Margins held steady as investments continued, and a major customer win began revenue contribution. Market uncertainty persists due to competitor consolidation.Based on NRC Health [NR…
Q2 saw 11% TRCV and 4% revenue growth year-over-year, with strong performance in Experience and Governance segments. Margins held steady as investments continued, and a major customer win began revenue contribution. Market uncertainty persists due to competitor consolidation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.